Bio-Connect

Goat anti-DLC1 (Isoforms 1 and 3)

EB06436
Everest Biotech
ApplicationsImmunoFluorescence, ELISA, ImmunoHistoChemistry
Product group Antibodies
TargetDLC1
100 ug
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Everest Biotech
  • Product Name
    Goat anti-DLC1 (Isoforms 1 and 3) Antibody
  • Delivery Days Customer
    5
  • Application Supplier Note
    Immunofluorescence: Expression of the protein seen in the cytoplasm and nucleus of U251 and U2OS cells. Recommended concentration: 10microg/ml.
  • Applications
    ImmunoFluorescence, ELISA, ImmunoHistoChemistry
  • Applications Supplier
    Pep-ELISA, IF, IHC
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Concentration
    0.5 mg/ml
  • Gene ID10395
  • Target name
    DLC1
  • Target description
    DLC1 Rho GTPase activating protein
  • Target synonyms
    ARHGAP7, HP, STARD12, p122-RhoGAP, rho GTPase-activating protein 7, Rho-GTPase-activating protein 7, START domain-containing protein 12, StAR-related lipid transfer (START) domain containing 12, deleted in liver cancer 1 protein, epididymis secretory sperm binding protein, rho-type GTPase-activating protein 7
  • Host
    Goat
  • Scientific Description
    RefSeq number(s): NP_872584.2; NP_079043.3. GeneIDs all Nonhuman: 50768 (mouse);. Purification: Antigen affinity purified. Names and symbols: DLC1; HP; ARHGAP7; STARD12; FLJ21120; p122-RhoGAP; deleted in liver cancer 1; Rho-GTPase-activating protein 7; START domain containing protein 12; StAR-related lipid; transfer protein 12; StAR-related lipid transfer (START) domain containing 12; deleted
  • Reactivity Supplier
    Human, Mouse, Pig
  • Storage Instruction
    -20°C
  • UNSPSC
    12352203

References

  • Ko FC, Yeung YS, Wong CM, et al. Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma. Liver Int. 2010,30(1):139-48. doi: 10.1111/j.1478-3231.2009.02133.x
    Read this paper